2021 Guideline for the Management of COPD Exacerbations: Emergency Medicine Association of Turkey (EMAT) / Turkish Thoracic Society (TTS) Clinical Practice Guideline Task Force

Nurettin Özgür Doğan, Yelda Varol, Nurdan Köktürk, Ersin Aksay, Aylin Özgen Alpaydın, Şeref Kerem Çorbacıoğlu, Gökhan Aksel, Ayşe Baha, Haldun Akoğlu, Sevilay Karahan, Elif Şen, Begüm Ergan, Başak Bayram, Serkan Yılmaz, Alev Gürgün, Mehmet Polatlı, Nurettin Özgür Doğan, Yelda Varol, Nurdan Köktürk, Ersin Aksay, Aylin Özgen Alpaydın, Şeref Kerem Çorbacıoğlu, Gökhan Aksel, Ayşe Baha, Haldun Akoğlu, Sevilay Karahan, Elif Şen, Begüm Ergan, Başak Bayram, Serkan Yılmaz, Alev Gürgün, Mehmet Polatlı

Abstract

Chronic obstructive pulmonary disease (COPD) is an important public health problem that manifests with exacerbations and causes serious mortality and morbidity in both developed and developing countries. COPD exacerbations usually present to emergency departments, where these patients are diagnosed and treated. Therefore, the Emergency Medicine Association of Turkey and the Turkish Thoracic Society jointly wanted to implement a guideline that evaluates the management of COPD exacerbations according to the current literature and provides evidence-based recommendations. In the management of COPD exacerbations, we aim to support the decision-making process of clinicians dealing with these patients in the emergency setting.

Keywords: Chronic obstructive pulmonary disease; dyspnea; emergency medicine; practice guideline (MeSH database).

Copyright: © 2021 Turkish Journal of Emergency Medicine.

Figures

Figure 5.6.1
Figure 5.6.1
Forest plot of the relationship between procalcitonin-guided care and mortality
Figure 6.4.1
Figure 6.4.1
Forest plot for the effect of long- and short-term antibiotic use on the incidence of side effects

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2021 Report. [Last accessed on 2021 May 25]. Available from: .
    1. [Last accessed on 2021 May 25]. Available from: .
    1. World Health Organization. Projections of Mortality and Causes of Death, 2016-2060. [Last accessed on 2021 May 25]. Available from:
    1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990- 2019: A systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–22.
    1. Halpin DM, Celli BR, Criner GJ, Frith P, Varela MV, Salvi S, et al. The GOLD summit on chronic obstructive pulmonary disease in low-and middle-income countries. Int J Tuberc Lung Dis. 2019;23:1131–41.
    1. TR Ministry of Health, 2019 Health Statistics Yearbook. [Last accessed on 2021 May 25]; Available from: .
    1. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
    1. Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
    1. Sterne JA, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
    1. Wedzicha JA, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, et al. Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49:1600791.
    1. Wedzicha JA, Martinez FJ, editors. Claude Lenfant. CRC Press; 2018. Chronic Obstructive Pulmonary Disease Exacerbations Lung Biology in Health and Disease. executive editor: ISBN: 9781138372450.
    1. Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, et al. COPD exacerbations: The importance of a standard definition. Respir Med. 2004;98:99–107.
    1. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of COPD. Updated 2021. [Last accessed on2021 Feb 01]; Available from:
    1. Agusti A, Faner R, Celli B, Rodriguez-Roisin R. Precision medicine in COPD exacerbations. Lancet Respir Med. 2018;6:657–9.
    1. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29:1224–38.
    1. Noell G, Cosío BG, Faner R, Monsó E, Peces-Barba G, de Diego A, et al. Multi-level differential network analysis of COPD exacerbations. Eur Respir J. 2017;50:1700075.
    1. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions pitfalls, challenges and opportunities for improvement. Eur Respir J. 2018;52:1801261.
    1. Turkish Thoracic Society's Perspective on the GOLD 2021 Chronic Obstructive Pulmonary Disease (COPD) Report 2021. [Last accessed on 2021 May 26]; Available from: .
    1. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–71.
    1. Chronic Obstructive Pulmonary Disease (Acute Exacerbation): Antimicrobial Prescribing. [Last accessed on 2021 May 26];NICE Guideline. 2018 December 05; Available from: .
    1. Bøtker MT, Kirkegaard H, Christensen EF, Terkelsen CJ. Dyspnea is a dangerous symptom in the pre-hospital setting. Scand J Trauma Resusc Emerg Med. 2015;23:O7.
    1. Prekker ME, Feemster LC, Hough CL, Carlbom D, Crothers K, Au DH, et al. The epidemiology and outcome of prehospital respiratory distress. Acad Emerg Med. 2014;21:543–50.
    1. Williams TA, Finn J, Fatovich D, Perkins GD, Summers Q, Jacobs I. Paramedic Differentiation of asthma and COPD in the prehospital setting ıs difficult. Prehosp Emerg Care. 2015;19:535–43.
    1. Pittet V, Burnand B, Yersin B, Carron PN. Trends of pre-hospital emergency medical services activity over 10 years: A population-based registry analysis. BMC Health Serv Res. 2014;14:380.
    1. Sneath E, Bunting D, Hazell W, Tippett V, Yang IA. Pre-hospital and emergency department pathways of care for exacerbations of chronic obstructive pulmonary disease (COPD) J Thorac Dis. 2019;11(Suppl 17):S2221–9.
    1. Ibsen S, Lindskou TA, Nickel CH, Kløjgård T, Christensen EF, Søvsø MB. Which symptoms pose the highest risk in patients calling for an ambulance? A population-based cohort study from Denmark. Scand J Trauma Resusc Emerg Med. 2021;29:59.
    1. Lindskou TA, Pilgaard L, Søvsø MB, Kløjgård TA, Larsen TM, Jensen FB, et al. Symptom, diagnosis and mortality among respiratory emergency medical service patients. PLoS One. 2019;14:e0213145.
    1. Kauppi W, Herlitz J, Magnusson C, Palmér L, Axelsson C. Characteristics and outcomes of patients with dyspnoea as the main symptom, suffered by prehospital emergency nurses – A retrospective observational study. BMC Emerg Med. 2020;20:67.
    1. Søvsø MB, Hermansen SB, Færk E, Lindskou TA, Ludwig M, Møller JM, et al. Diagnosis and mortality of emergency department patients in the North Denmark region. BMC Health Serv Res. 2018;18:548.
    1. Kelly AM, Keijzers G, Klim S, Graham CA, Craig S, Kuan WS, et al. An observational study of dyspnea in emergency departments: The Asia, Australia, and New Zealand Dyspnea in emergency departments study (AANZDEM) Acad Emerg Med. 2017;24:328–36.
    1. Lindvig KP, Brøchner AC, Lassen AT, Mikkelsen S. Prehospital prognosis is difficult in patients with acute exacerbation of chronic obstructive pulmonary disease. Scand J Trauma Resusc Emerg Med. 2017;25:106.
    1. Tully B. Prehospital Care for Dyspnea. EMS World Issue. 2020. Apr, [Last accessed on 2021 Apr 28]. Available from: .
    1. Snyder SR, Kivlehan SM, Collopy KT. COPD exacerbation. What are the keys to treating it in the prehospital setting? EMS World. 2015;44:54–60.
    1. Beygui F, Castren M, Brunetti ND, Rosell-Ortiz F, Christ M, Zeymer U, et al. ACCA study group on pre-hospital care. Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC. Eur Heart J Acute Cardiovasc Care. 2020;9(Suppl 1):59–81.
    1. Merelman A, Levitan R. A modern approach to basic airway management. J Emerg Med Serv. 2018;43:4.
    1. Hunter CL, Silvestri S, Ralls G, Papa L. Prehospital end-tidal carbon dioxide differentiates between cardiac and obstructive causes of dyspnoea. Emerg Med J. 2015;32:453–6.
    1. Klemen P, Golub M, Grmec S. Combination of quantitative capnometry N-terminal pro-brain natriuretic peptide, and clinical assessment in differentiating acute heart failure from pulmonary disease as cause of acute dyspnea in prehospital emergency setting: Study of diagnostic accuracy. Croat Med J. 2009;50:133–42.
    1. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: Randomized controlled trial. BMJ. 2010;341:c5462.
    1. Kopsaftis Z, Carson-Chahhoud KV, Austin MA, Wood-Baker R. Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;1:CD005534.
    1. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald VM, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust. 2017;207:436–42.
    1. O'Driscoll BR, Howard LS, Earis J, Mak V. British Thoracic Society guideline for oxygen use in adults in healthcare and emergency settings. BMJ Open Respir Res. 2017;4:e000170.
    1. Luiz T, Kumpch M, Grüttner J, Madler C, Viergutz T. Prehospital CPAP therapy by emergency physicians in patients with acute respiratory failure due to acute cardiogenic pulmonary edema or acutely exacerbated COPD. In Vivo. 2016;30:133–9.
    1. Hensel M, Strunden MS, Tank S, Gagelmann N, Wirtz S, Kerner T. Prehospital non-invasive ventilation in acute respiratory failure is justified even if the distance to hospital is short. Am J Emerg Med. 2019;37:651–6.
    1. Thompson J, Petrie DA, Ackroyd-Stolarz S, Bardua DJ. Out-of-hospital continuous positive airway pressure ventilation versus usual care in acute respiratory failure: A randomized controlled trial. Ann Emerg Med. 2008;52:232–41, 241.e1.
    1. Schmidbauer W, Ahlers O, Spies C, Dreyer A, Mager G, Kerner T. Early prehospital use of non-invasive ventilation improves acute respiratory failure in acute exacerbation of chronic obstructive pulmonary disease. Emerg Med J. 2011;28:626–7.
    1. Bakke SA, Botker MT, Riddervold IS, Kirkegaard H, Christensen EF. Continuous positive airway pressure and noninvasive ventilation in prehospital treatment of patients with acute respiratory failure: A systematic review of controlled studies. Scand J Trauma Resusc Emerg Med. 2014;22:69.
    1. National Association of State EMS Officials. (). National model EMS clinical guidelines. Version 2.0. 2017. [Last accessed on 2021 Apr 28]. Available from: .
    1. Hodroge SS, Glenn M, Breyre A, Lee B, Aldridge NR, Sporer KA, et al. Adult patients with respiratory distress: Current evidence-based recommendations for prehospital care. West J Emerg Med. 2020;21:849–57.
    1. Ringbaek TJ, Terkelsen J, Lange P. Outcomes of acute exacerbations in COPD in relation to pre-hospital oxygen therapy. Eur Clin Respir J. 2015 May 11;2
    1. Global Strategy for the Diagnosis Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report. [Last accessed on 2021 Apr 28]. Available from: .
    1. van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev. 2016 Aug 29;2016(8):CD011826.
    1. Thompson M, Wise S, Rodenberg H. A preliminary comparison of levalbuterol and albuterol in prehospital care. J Emerg Med. 2004;26:271–7.
    1. Sagarin MJ. A preliminary comparison of levalbuterol and albuterol in prehospital care. J Emerg Med. 2005;28:349.
    1. Zehner WJ, Jr, Scott JM, Iannolo PM, Ungaro A, Terndrup TE Terbutaline vs. albuterol for out-of-hospital respiratory distress: Randomized, double-blind trial. Acad Emerg Med. 1995;2:686–91.
    1. Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Sep 1;(9):CD001288.
    1. [Last accessed on 2021 May 04]. Turkish Thoracic Society's Perspective on the GOLD 2017 Chronic Obstructive Pulmonary Disease (COPD) Report. Available from: .
    1. Wijesinghe M, Perrin K, Healy B, Hart K, Clay J, Weatherall M, et al. Pre-hospital oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Intern Med J. 2011;41:618–22.
    1. Aleva FE, Voets LW, Simons SO, de Mast Q, van der Ven AJ, Heijdra YF. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: A systematic review and meta-analysis. Chest. 2017;151:544–54.
    1. Shapira-Rootman M, Beckerman M, Soimu U, Nachtigal A, Zeina AR. The prevalence of pulmonary embolism among patients suffering from acute exacerbations of chronic obstructive pulmonary disease. Emerg Radiol. 2015;22:257–60.
    1. Stiell IG, Perry JJ, Clement CM, Brison RJ, Rowe BH, Aaron SD, et al. Clinical validation of a risk scale for serious outcomes among patients with chronic obstructive pulmonary disease managed in the emergency department. CMAJ. 2018;190:E1406–13.
    1. Steer J, Gibson J, Bourke SC. The DECAF Score: Predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67:970–6.
    1. Global Strategy for Diagnosis Management and Prevention of COPD. The Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 2021 Report. [Last accessed on 2021 May 04]; Available from:
    1. Sevinç C, Uzun O, editors. Thorax Books. Respiratory emergencies. .
    1. Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM, Siegel MD. 4th Ed. Vol. 1. McGraw-Hill Education; Fishman Pulmonary Diseases and Disorders; p. 741.
    1. Turkish Thoracic Society, COPD Prevention, Diagnosis and Treatment Report. 2014:60. .
    1. Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease. [Last accessed on 2021 May 05]. Available from:
    1. Kelly AM, Klim S. Agreement between arterial and venous pH and pCO2 in patients undergoing non-invasive ventilation in the emergency department. Emerg Med Australas. 2013;25:203–6.
    1. Woods M, Hodgson D. Towards evidence-based emergency medicine: Best BETs from the Manchester Royal Infirmary. BET 2: In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? Emerg Med J. 2015;32:251–3.
    1. Lim BL, Kelly AM. A meta-analysis on the utility of peripheral venous blood gas analyzes in exacerbations of chronic obstructive pulmonary disease in the emergency department. Eur J Emerg Med. 2010;17:246–8.
    1. Emerman CL, Connors AF, Lukens TW, Effron D, May ME. Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med. 1989;18:523–7.
    1. Wong EK, Lee PC, Ansary S, Asha S, Wong KK, Yee BJ, et al. Role of venous blood gases in hypercapnic respiratory failure chronic obstructive pulmonary disease patients presenting to the emergency department. Intern Med J. 2019;49:834–7.
    1. Byrne AL, Bennett M, Chatterji R, Symons R, Pace NL, Thomas PS. Peripheral venous and arterial blood gas analysis in adults: Are they comparable? A systematic review and meta-analysis. Respirology. 2014;19:168–75.
    1. Byrne AL, Bennett MH, Pace NL, Thomas P. Peripheral venous blood gas analysis versus arterial blood gas analysis for the diagnosis of respiratory failure and metabolic disturbance in adults. Cochrane Database Syst Rev 2013. 2013:CD010841.
    1. Domaradzki L, Gosala S, Iskandarani K, Van de Louw A. Is venous blood gas performed in the emergency department predictive of outcome during acute on chronic hypercarbic respiratory failure? Clin Respir J. 2018;12:1849–57.
    1. Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax. 2016;71(Suppl 2):i1–35.
    1. Tyagi D, Govindagoudar MB, Jakka S, Chandra S, Chaudhry D. Correlation of PaCO2 and ETCO2 in COPD patients with exacerbation on mechanical ventilation. Indian J Crit Care Med. 2021;25:305–9.
    1. Roberts JR. 7th ed. Philadelphia, USA: Elsevier; 2019. Roberts and Hedges' Clinical Procedures in Emergency Medicine and Acute Care; p. 1534.
    1. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309:2353–61.
    1. Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, et al. ECLIPSE Study Investigators Lessons from ECLIPSE: A review of COPD biomarkers. Thorax. 2014;69:666–72.
    1. Noell G, Cosío BG, Faner R, Monsó E, Peces-Barba G, de Diego A, et al. Multi-level differential network analysis of COPD exacerbations. Eur Respir J. 2017;50:1700075.
    1. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic issue is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One. 2012;7:e37483.
    1. Fattouh M, Alkady O. Inflammatory biomarkers in chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc. 2014;63:799–804.
    1. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second overtime in COPD. N Engl J Med. 2011;365:1184–92.
    1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.
    1. Stiell IG, Clement CM, Aaron SD, Rowe BH, Perry JJ, Brison RJ, et al. Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: A prospective cohort study. CMAJ. 2014;186:E193–204.
    1. Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: Cause effects, and disease progression. Int J Chron Obstruct Pulmon Dis. 2011;6:199–208.
    1. Toft-Petersen AP, Torp-Pedersen C, Weinreich UM, Rasmussen BS. Association between hemoglobin and prognosis in patients admitted to hospital for COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2813–20.
    1. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet. 2000;356:1480–5.
    1. Cheng SL. Blood eosinophils and inhaled corticosteroids in patients with COPD: Systematic review and meta-analysis shih-lung. Int J Chron Obstruct Pulmon Dis. 2018;13:2775–84.
    1. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47:1374–82.
    1. Hasegawa K, Camargo CA., Jr Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology. 2016;21:761–4.
    1. Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27:170103.
    1. Kandemir Y, Doğan NÖ, Yaka E, Pekdemir M, Yılmaz S. Clinical characteristics of neutrophilic eosinophilic and mixed-type exacerbation phenotypes of COPD. Am J Emerg Med. 2021;45:237–41.
    1. Long GH, Southworth T, Kolsum U, Donaldson GC, Wedzicha JA, Brightling CE, et al. The stability of blood eosinophils in chronic obstructive pulmonary disease. Respir Res. 2020;21:15.
    1. Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10:S214–9.
    1. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867–74.
    1. Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas-Jones E, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med. 2019;381:111–20.
    1. Prins HJ, Duijkers R, van der Valk P, Schoorl M, Daniels JM, van der Werf TS, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J. 2019;53:1802014.
    1. Grolimund E, Kutz A, Marlowe RJ, Vögeli A, Alan M, Christ-Crain M, et al. ProHOSP study group. Long-term prognosis in COPD exacerbation: Role of biomarkers, clinical variables and exacerbation type. COPD. 2015;12:295–305.
    1. Pavasini R, Tavazzi G, Biscaglia S, Guerra F, Pecoraro A, Zaraket F, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chron Respir Dis. 2017;14:117–26.
    1. Raluca H, Maria A, Magda B. Natriuretic peptides in heart failure coexisting with chronic obstructive pulmonary disease. Exp Clin Cardiol. 2014;20:1606–14.
    1. Guo X, Nie H, Chen Q, Chen S, Deng N, Li R, et al. The role of plasma N-terminal brain natriuretic pro-peptide in diagnosing elderly patients with acute exacerbation of COPD concurrent with left heart failure. Int J Chron Obstruct Pulmon Dis. 2018;13:2931–40.
    1. Laribi S, Pemberton CJ, Kirwan L, Nouira S, Turkdogan K, Yilmaz MB, et al. GREAT (Global Research on Acute Conditions Team) network. Mortality and acute exacerbation of COPD: A pilot study on the influence of myocardial injury. Eur Respir J. 2017;49:1700096.
    1. Wang M, Lin EP, Huang LC, Li CY, Shyr Y, Lai CH. Mortality of cardiovascular events in patients With COPD and preceding hospitalization for acute exacerbation. Chest. 2020;158:973–85.
    1. Adamson PD, Anderson JA, Brook RD, Calverley PM, Celli BR, Cowans NJ, et al. Cardiac troponin I and cardiovascular risk in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2018;72:1126–37.
    1. Couturaud F, Bertoletti L, Pastre J, Roy PM, Le Mao R, Gagnadoux F, et al. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms. JAMA. 2021;325:59–68.
    1. Aleva FE, Voets LW, Simons SO, de Mast Q, van der Ven AJ, Heijdra YF. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: A systematic review and meta-analysis. Chest. 2017;151:544–54.
    1. Fruchter O, Yigla M, Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2015;349:29–35.
    1. Hu G, Wu Y, Zhou Y, Wu Z, Wei L, Li Y, et al. Prognostic role of D-dimer for in-hospital and 1-year mortality in exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2729–36.
    1. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. ESC scientific document group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) Eur Heart J. 2020;41:543–603.
    1. Fabbian F, De Giorgi A, Manfredini F, Lamberti N, Forcellini S, Storari A, et al. Impact of renal dysfunction on in-hospital mortality of patients with severe chronic obstructive pulmonary disease: A single-center Italian study. Int Urol Nephrol. 2016;48:1121–7.
    1. Barakat MF, McDonald HI, Collier TJ, Smeeth L, Nitsch D, Quint JK. Acute kidney injury in stable COPD and at exacerbation. Int J Chron Obstruct Pulmon Dis. 2015;10:2067–77.
    1. Wan X, Chen D, Tan Y, Ma M, Zhang F, Liu Z, et al. Incidence, risk factors, and prognostic ımplications of acute kidney ınjury in patients with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1085–92.
    1. Minakata Y, Sugiura H, Yamagata T, Yanagisawa S, Ichikawa T, Koarai A, et al. Prevalence of COPD in primary care clinics: Correlation with non-respiratory diseases. Intern Med. 2008;47:77–82.
    1. Viglino D, Jullian-Desayes I, Minoves M, Aron-Wisnewsky J, Leroy V, Zarski JP, et al. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 2017;49:1601923.
    1. Chalela R, González-García JG, Chillarón JJ, Valera-Hernández L, Montoya-Rangel C, Badenes D, et al. Impact of hyponatremia on mortality and morbidity in patients with COPD exacerbations. Respir Med. 2016;117:237–42.
    1. Goudis CA, Konstantinidis AK, Ntalas IV, Korantzopoulos P. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol. 2015;199:264–73.
    1. Holtzman D, Aronow WS, Mellana WM, Sharma M, Mehta N, Lim J, et al. Electrocardiographic abnormalities in patients with severe versus mild or moderate chronic obstructive pulmonary disease followed in an academic outpatient pulmonary clinic. Ann Noninvasive Electrocardiol. 2011;16:30–2.
    1. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Lancet Respir Med. 2015;3:631–9.
    1. Bayer AJ, Chadha JS, Farag RR, Pathy MS. Changing presentation of myocardial infarction with increasing old age. J Am Geriatr Soc. 1986;34:263–6.
    1. Gregoratos G. Clinical manifestations of acute myocardial infarction in older patients. Am J Geriatr Cardiol. 2001;10:345–7.
    1. Terzano C, Romani S, Conti V, Paone G, Oriolo F, Vitarelli A. Atrial fibrillation in the acute hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014;18:2908–17.
    1. Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med. 2012;106:1134–8.
    1. McCord J, Borzak S. Multifocal atrial tachycardia. Chest. 1998;113:203–9.
    1. Custer AM, Yelamanchili VS, Lappin SL. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021; 2020. Jul 19, Multifocal Atrial Tachycardia.
    1. Radiopedia. [Last accessed on 2021 May 05]. Available from: .
    1. Ramakrishnan S, Janssens W, Burgel PR, Contoli M, Franssen FME, Greening NJ, et al. Standardization of clinical assessment, management and follow-up of acute hospitalized exacerbation of COPD: A Europe-Wide consensus. Int J Chron Obstruct Pulmon Dis. 2021;16:321–32.
    1. Park HJ, Kim SH, Kim HC, Lee BY, Lee SW, Lee JS, et al. Utility of computed tomography in a differential diagnosis for the patients with an ınitial diagnosis of chronic obstructive pulmonary disease exacerbation. Tuberc Respir Dis (Seoul) 2019;82:234–41.
    1. Cheng T, Wan H, Cheng Q, Guo YI, Qian Y, Fan L, et al. Computed tomography manifestation of acute exacerbation of chronic obstructive pulmonary disease: A pilot study. Exp Ther Med. 2016;11:519–29.
    1. Hackx M, Ghaye B, Coche E, Muylem AV, Gevenois PA. Severe COPD exacerbation: CT features. COPD. 2015;12:38–45.
    1. Labaki WW, Martinez CH, Martinez FJ, Galbán CJ, Ross BD, Washko GR, et al. The Role of chest computed tomography in the evaluation and management of the patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:1372–9.
    1. Turkish Thoracic Society Pulmonary Thromboembolism Diagnosis and Treatment Consensus Report. [Last accessed on 2021 May 05]. ISBN: 978-625-409-811-6. Release Date: January 2021. Available from: .
    1. Tabak YP, Sun X, Johannes RS, Gupta V. Shorr AF. Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: Development and validation of a simple risk score. Arch Intern Med. 2009;169:1595–602.
    1. Steer J, Gibson J, Bourke SC. The DECAF score: Predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67:970–6.
    1. Stiell IG, Clement CM, Aaron SD, Rowe BH, Perry JJ, Brison RJ, et al. Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: A prospective cohort study. CMAJ. 2014;186:E193–204.
    1. Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S. Determining prognosis in acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:467–75.
    1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) ınvestigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.
    1. Lacoma A, Prat C, Andreo F, Domínguez J. Biomarkers in the management of COPD. Eur Respir Rev. 2009;18:96–104.
    1. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: The evolving clinical challenge. Chest. 2012;141:396–405.
    1. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: Past present and future. BMC Med. 2011;9:107.
    1. Vijayan AL, Vanimaya, Ravindran S, Saikant R, Lakshmi S, Kartik R, et al. Procalcitonin: A promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care. 2017;5:51.
    1. Bassetti M, Russo A, Righi E, Dolso E, Merelli M, D'Aurizio F, et al. Role of procalcitonin in predicting etiology in bacteremic patients: Report from a large single-center experience. J Infect Public Health. 2020;13:40–5.
    1. Hankey B, Riley B. Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. BET 1: Use of a procalcitonin algorithm to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality. Emerg Med J. 2015;32:493–5.
    1. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: A meta-analysis. Eur Respir Rev. 2017;26:160073.
    1. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867–74.
    1. Bircan A, Gokirmak M, Kilic O, Ozturk O, Akkaya A. C-reactive protein levels in patients with chronic obstructive pulmonary disease: Role of infection. Med Princ Pract. 2008;17:202–8.
    1. Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:491–7.
    1. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Müllerova H, Donaldson GC, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29:527–34.
    1. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058–67.
    1. Phua J, Koay ES, Zhang D, Tai LK, Boo XL, Lim KC, et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J. 2006;28:695–702.
    1. Müller B, Süess E, Schuetz P, Müller C, Bingisser R, Bergmann A, et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med. 2006;260:568–76.
    1. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:1065–72.
    1. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. ProHOSP study group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA. 2009;302:1059–66.
    1. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–7.
    1. Daniels JM, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, et al. Procalcitonin vs. C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010;138:1108–15.
    1. Townsend J, Adams V, Galiatsatos P, Pearse D, Pantle H, Masterson M, et al. Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower respiratory tract ınfections in a United States medical center: Results of a clinical trial. Open Forum Infect Dis. 2018;5:ofy327.
    1. Wang JX, Zhang SM, Li XH, Zhang Y, Xu ZY, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: A prospective randomized controlled trial. Int J Infect Dis. 2016;48:40–5.
    1. Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: A randomized noninferiority trial. PLoS One. 2015;10:e0118241.
    1. Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1381–9.
    1. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19.
    1. Zou Y, Zhu Z, Zhang Y. Significance of serum procalcitonin combined with C-reactive protein in diagnosis of acute exacerbation of chronic obstructive pulmonary disease and guidance of antibiotics therapy. Int J Clin Exp Med. 2018;11:11070–8.
    1. Ulrich RJ, McClung D, Wang BR, Winters S, Flanders SA, Rao K. Introduction of Procalcitonin Testing and Antibiotic Utilization for acute exacerbations of chronic obstructive pulmonary disease. Infect Dis (Auckl) 2019;12:1178633719852626.
    1. Ruiz-González A, Giménez A, Gómez-Arbonés X, Soler-González J, Sánchez V, Falguera M, et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology. 2007;12:117–21.
    1. Vermeersch K, Gabrovska M, Aumann J, Demedts IK, Corhay JL, Marchand E, et al. Azithromycin during acute chronic obstructive pulmonary disease exacerbations requiring hospitalization (BACE). A multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2019;200:857–68.
    1. Vermeersch K, Belmans A, Bogaerts K, Gyselinck I, Cardinaels N, Gabrovska M, et al. Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo – A post hoc analysis of the BACE randomized controlled trial. Respir Res. 2019;20:237.
    1. Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012;40:17–27.
    1. van Velzen P, Ter Riet G, Bresser P, Baars JJ, van den Berg BT, van den Berg JW, et al. Doxycycline for outpatient-treated acute exacerbations of COPD: A randomised double-blind placebo-controlled trial. Lancet Respir Med. 2017;5:492–9.
    1. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: A randomised placebo-controlled trial. Lancet. 2001;358:2020–5.
    1. Elmes PC, King TK, Langlands JH, Mackay JA, Wallace WF, Wade OL, et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J. 1965;2:904–8.
    1. Pines A, Raafat H, Plucinski K, Greenfield JS, Linsell WD, Solari ME. Demethylchlortetracycline, lymecycline and methacycline compared in patients with purulent exacerbations of bronchitis. Br J Dis Chest. 1968;62:19–26.
    1. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953–64.
    1. Allegra L, Konietzko N, Leophonte P, Hosie J, Pauwels R, Guyen JN, et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother. 1996;37(Suppl A):93–104.
    1. Joyner KR, Walkerly A, Seidel K, Walsh N, Damshekan N, Perry T, et al. Comparison of narrow-versus broad-spectrum antibiotics in elderly patients with acute exacerbations of chronic obstructive pulmonary disease. J Pharm Pract. 2020 Jul 10;:897190020938190.
    1. Kiser TH, Reynolds PM, Moss M, Burnham EL, Ho PM, Vandivier RW, et al. Impact of macrolide antibiotics on hospital readmissions and other clinically ımportant outcomes in critically Ill patients with acute exacerbations of chronic obstructive pulmonary disease: A propensity score-matched cohort study. Pharmacotherapy. 2019;39:242–52.
    1. Bremmer DN, Moffa MA, Ma K, Bean HR, Snatchko J, Trienski TL, et al. Acute exacerbations of chronic obstructive pulmonary disease with a low procalcitonin concentration: Impact of antibiotic therapy. Clin Infect Dis. 2019;68:725–30.
    1. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) J Hosp Med. 2010;5:261–7.
    1. Stefan MS, Rothberg MB, Shieh MS, Pekow PS, Lindenauer PK. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest. 2013;143:82–90.
    1. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
    1. Roede BM, Bresser P, El Moussaoui R, Krouwels FH, van den Berg BT, Hooghiemstra PM, et al. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: A randomised, double-blind study. Clin Microbiol Infect. 2007;13:284–90.
    1. Gotfried M, Notario G, Spiller J, Palmer R, Busman T. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr Med Res Opin. 2005;21:245–54.
    1. Lorenz J. Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis. Chemotherapy. 1998;44(Suppl 1):15–8.
    1. Gotfried MH, DeAbate CA, Fogarty C, Mathew CP, Sokol WN. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther. 2001;23:97–107.
    1. DeAbate CA, Bettis R, Munk ZM, Fleming H, Munn NJ, Riffer E, et al. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther. 1999;21:172–88.
    1. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 2005;49:153–60.
    1. Wasilewski MM, Johns D, Sides GD. Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;43:541–8.
    1. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2001;18:503–12.
    1. Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The bronchitis study group. Respir Med. 2000;94:18–27.
    1. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Am J Respir Crit Care Med. 2002;165:698–703.
    1. Ställberg B, Selroos O, Vogelmeier C, Andersson E, Ekström T, Larsson K. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res. 2009;10:11.
    1. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29:660–7.
    1. Yilmazel Ucar E, Araz O, Meral M, Sonkaya E, Saglam L, Kaynar H, et al. Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: A randomized control trial. Med Sci Monit. 2014;20:513–20.
    1. Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med. 1995;333:499–506.
    1. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:967–75.
    1. Bilgic H, Karadağ M, Umut S, Erdinç E. Bursa: Galenos Yayıncılık, Toraks Kitapları;; 2008. Chronic Obstructive Pulmonary Disease from Definition to Treatment. .
    1. McCrory DC, Brown CD. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2001. 2001;(2):CD002984.
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2021 Report) [Last accessed on 2020 Dec 06]. Available from: .
    1. Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest. 2005;128:48–54.
    1. Bardsley G, Pilcher J, McKinstry S, Shirtcliffe P, Berry J, Fingleton J, et al. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: A randomised controlled trial. BMC Pulm Med. 2018;18:157.
    1. Edwards L, Perrin K, Williams M, Weatherall M, Beasley R. Randomized controlled crossover trial of the effect on PtCO2 of oxygen-driven versus air-driven nebulisers in severe chronic obstructive pulmonary disease. Emerg Med J. 2012;29:894–8.
    1. Costello RW, Jacoby DB, Fryer AD. Pulmonary neuronal M2 muscarinic receptor function in asthma and animal models of hyperreactivity. Thorax. 1998;53:613–6.
    1. McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(4):CD003900.
    1. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax. 1995;50:834–7.
    1. van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev. 2016 Aug 29;2016(8):CD011826.
    1. Duffy N, Walker P, Diamantea F, Calverley PM, Davies L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: A prospective randomized controlled trial. Thorax. 2005;60:713–7.
    1. Köktürk N, Gürgün A, Şen E, Kocabaş A, Polatlı M, Naycı SA, et al. The view of the Turkish Thoracic Society on the report of the GOLD 2017 global strategy for the diagnosis, management, and prevention of COPD. Turk Thorac J. 2017;18:57–64.
    1. Edwards L, Shirtcliffe P, Wadsworth K, Healy B, Jefferies S, Weatherall M, et al. Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: A randomised double-blind placebo-controlled trial. Thorax. 2013;68:338–43.
    1. Hogg J, Mulrennan S, Everett C. A single center double-blind placebo-controlled pilot study into the use of intravenous magnesium sulphate for the treatment of acute exacerbation of COPD (abstract) Eur Respir J. 2004;(Suppl 48):343p.
    1. Skorodin MS, Tenholder MF, Yetter B, Owen KA, Waller RF, Khandelwahl S, et al. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 1995;155:496–500.
    1. Dobler CC, Morrow AS, Farah MH, Beuschel B, Majzoub AM, Wilson ME, et al. Rockville (MD): Agency for Healthcare Research and Quality (US): 2019. Oct, Pharmacologic and Nonpharmacologic Therapies in Adult Patients with Exacerbation of COPD: A Systematic Review. Report No.:19(20)-EHC024-EF.
    1. Nava S, Fanfulla F, editors. Springer Verlag, Italy: Springer; 2014. Noninvasive Artificial Ventilation: How, When, Why?
    1. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet. 2009;374:250–9.
    1. Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. BTS standards of care committee member, British Thoracic Society/Intensive Care Society Acute Hypercapnic Respiratory Failure guideline development group, On behalf of the British Thoracic Society standards of Care committee. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax. 2016;71(Suppl 2):ii1–35.
    1. Bello G, De Pascale G, Antonelli M. Noninvasive ventilation: Practical advice. Curr Opin Crit Care. 2013;19:1–8.
    1. Roberts CM, Stone RA, Buckingham RJ, Pursey NA, Lowe D. Acidosis, non-invasive ventilation and mortality in hospitalized COPD exacerbations. Thorax. 2011;66:43–8.
    1. Nava S, Navalesi P, Conti G. Time of non-invasive ventilation. Intensive Care Med. 2006;32:361–70.
    1. Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: Noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50:1602426.
    1. Ergan B, Nasiłowski J, Winck JC. How should we monitor patients with acute respiratory failure treated with noninvasive ventilation? Eur Respir Rev. 2018;27:170101.
    1. Brochard L, Isabey D, Piquet J, Amaro P, Mancebo J, Messadi AA, et al. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. N Engl J Med. 1990;323:1523–30.
    1. Carlucci A, Pisani L, Ceriana P, Malovini A, Nava S. Patient-ventilator asynchronies: May the respiratory mechanics play a role? Crit Care. 2013;17:R54.
    1. Ozyilmaz E, Ugurlu AO, Nava S. Timing of noninvasive ventilation failure: Causes, risk factors, and potential remedies. BMC Pulm Med. 2014;14:19.
    1. Nishimura M. High-flow nasal cannula oxygen therapy devices. Respir Care. 2019;64:735–42.
    1. Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2017;195:1207–15.
    1. Thille AW, Yoshida T. High pressure versus high flow: What should we target in acute respiratory failure? Am J Respir Crit Care Med. 2020;201:265–6.
    1. Grieco DL, Menga LS, Raggi V, Bongiovanni F, Anzellotti GM, Tanzarella ES, et al. Physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2020;201:303–12.
    1. Frat JP, Ragot S, Girault C, Perbet S, Prat G, Boulain T, et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: A post-hoc analysis of a randomised trial. Lancet Respir Med. 2016;4:646–52.
    1. Ou X, Hua Y, Liu J, Gong C, Zhao W. Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: A meta-analysis of randomized controlled trials. CMAJ. 2017;189:E260–7.
    1. O'Driscoll BR, Howard LS, Earis J, Mak V. British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72:i1–90.
    1. Pisani L, Fasano L, Corcione N, Comellini V, Musti MA, Brandao M, et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. Thorax. 2017;72:373–5.
    1. Pisani L, Betti S, Biglia C, Fasano L, Catalanotti V, Prediletto I, et al. Effects of high-flow nasal cannula in patients with persistent hypercapnia after an acute COPD exacerbation: A prospective pilot study. BMC Pulm Med. 2020;20:12.
    1. Şancı E, Ercan Coşkun F, Bayram B. Impact of high-flow nasal cannula on arterial blood gas parameters in the emergency department. Cureus. 2020;12:e10516.
    1. Kim ES, Lee H, Kim SJ, Park J, Lee YJ, Park JS, et al. Effectiveness of high-flow nasal cannula oxygen therapy for acute respiratory failure with hypercapnia. J Thorac Dis. 2018;10:882–8.
    1. Huang Y, Lei W, Zhang W, Huang JA. High-flow nasal cannula in hypercapnic respiratory failure: A systematic review and meta-analysis. Can Respir J. 2020;2020:7406457.
    1. Attaway AH, Faress J, Jacono F, Dasarathy S. Acute responses to oxygen delivery via high flow nasal cannula in patients with severe chronic obstructiv pulmonary disease-HFNC and severe COPD. J Clin Med. 2021;10:1814.
    1. Pilcher J, Eastlake L, Richards M, Power S, Cripps T, Bibby S, et al. Physiological effects of titrated oxygen via nasal high-flow cannulae in COPD exacerbations: A randomized controlled cross-over trial. Respirology. 2017;22:1149–55.
    1. Doshi P, Whittle JS, Bublewicz M, Kearney J, Ashe T, Graham R, et al. High-velocity nasal ınsufflation in the treatment of respiratory failure: A randomized clinical trial. Ann Emerg Med. 2018;72:73–83.e5.
    1. Lee MK, Choi J, Park B, Kim B, Lee SJ, Kim SH, et al. High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. Clin Respir J. 2018;12:2046–56.
    1. Sun J, Li Y, Ling B, Zhu Q, Hu Y, Tan D, et al. High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: An observational cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1229–37.
    1. Wedzicha JA, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, et al. Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49:1600791.
    1. Website: Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2021 Report. [Last accessed on 2021 May 25]. Available from: .
    1. Ergan B, Nasiłowski J, Winck JC. How should we monitor patients with acute respiratory failure treated with noninvasive ventilation? Eur Respir Rev. 2018;27:170101.
    1. Garcia-Gutierrez S, Quintana JM, Barrio I, Bare M, Fernandez N, Vidal S, et al. Application of appropriateness criteria for hospitalization in COPD exacerbation. Intern Emerg Med. 2013;8:349–57.
    1. Garcia-Gutierrez S, Quintana JM, Bilbao A, Unzurrunzaga A, Esteban C, Baré M, et al. IRYSS-COPD appropriateness study (IRYSS-COPD) group. Validity of criteria for hospital admission in exacerbations of COPD. Int J Clin Pract. 2014;68:820–9.
    1. Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F. Predictive model of hospital admission for COPD exacerbation. Respir Care. 2015;60:1288–94.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe